news
« BACK
Health - Pharmacology - 16.11.2021
Health - Pharmacology - 15.11.2021
Health - Pharmacology - 08.11.2021
Pharmacology - Health - 01.11.2021
Health - Pharmacology - 25.10.2021
Health - Pharmacology - 05.10.2021
Health - Pharmacology - 27.09.2021
Health - Pharmacology - 23.09.2021
Health - Pharmacology - 21.09.2021
Pharmacology - Health - 07.09.2021
Health - Pharmacology - 17.06.2021
Health - Pharmacology - 28.01.2021
Pharmacology
Results 41 - 52 of 52.
Global study offers new insight on heart valve surgery
By Celine Zadorsky, Special to Western News Researchers at Western and Lawson Health Research Institute played a leading role in a new global study that will change the way surgeons repair leaky valves in the heart. Leaky valve is one of the most common heart conditions, and it often does not present any symptoms. Many patients don't even realize they have a leaky valve, often presenting to doctors only when they are in the late stage of the disease.
By Celine Zadorsky, Special to Western News Researchers at Western and Lawson Health Research Institute played a leading role in a new global study that will change the way surgeons repair leaky valves in the heart. Leaky valve is one of the most common heart conditions, and it often does not present any symptoms. Many patients don't even realize they have a leaky valve, often presenting to doctors only when they are in the late stage of the disease.
New biomarkers for type 1 diabetes
A new study identifies circulating proteins as potential therapeutic targets and screening tools for type 1 diabetes. A research team led by Dr. Despoina Manousaki of the CHU Sainte-Justine Research Centre and the Université de Montréal has identified three circulating proteins as promising molecules for the development of drugs and early detection tools for patients with type 1 diabetes.
A new study identifies circulating proteins as potential therapeutic targets and screening tools for type 1 diabetes. A research team led by Dr. Despoina Manousaki of the CHU Sainte-Justine Research Centre and the Université de Montréal has identified three circulating proteins as promising molecules for the development of drugs and early detection tools for patients with type 1 diabetes.
COVID-19: The older you are, the more antibodies you have
Université de Montréal chemists looked at lab samples of patients who recovered from a mild case of COVID-19 and found that those over 50 produced more antibodies against the SARS-CoV-2 virus. With the emergence of SARS-CoV-2 variants worldwide, the pandemic's spread is accelerating. A research team led by Joelle Pelletier and Jean-François Masson, both professors in Université de Montréal's Department of Chemistry, wanted to find out whether natural infection or vaccination led to more protective antibodies being generated.
Université de Montréal chemists looked at lab samples of patients who recovered from a mild case of COVID-19 and found that those over 50 produced more antibodies against the SARS-CoV-2 virus. With the emergence of SARS-CoV-2 variants worldwide, the pandemic's spread is accelerating. A research team led by Joelle Pelletier and Jean-François Masson, both professors in Université de Montréal's Department of Chemistry, wanted to find out whether natural infection or vaccination led to more protective antibodies being generated.
New hope for Duchenne muscular dystrophy patients
Research team at CHU Sainte-Justine has discovered a more effective and less toxic targeted treatment for Duchenne muscular dystrophy. It's called Resolvin-D2. A research team led by Nicolas Dumont, a researcher at CHU Sainte-Justine and professor at the Université de Montréal, has discovered a new therapeutic molecule, Resolvin-D2.
Research team at CHU Sainte-Justine has discovered a more effective and less toxic targeted treatment for Duchenne muscular dystrophy. It's called Resolvin-D2. A research team led by Nicolas Dumont, a researcher at CHU Sainte-Justine and professor at the Université de Montréal, has discovered a new therapeutic molecule, Resolvin-D2.
New AI can predict virus mutations and help create more effective treatments and vaccines
New technology can contribute to other medical treatments, such as cancer. Researchers have developed a new method that uses artificial intelligence to foresee the most likely mutations of pathogens like SARS-COV-2, the virus that causes COVID-19. The new research has implications for the rapid development of vaccines, treatments and diagnostic tests that would be much less likely to be impacted by new or emerging variants of concern.
New technology can contribute to other medical treatments, such as cancer. Researchers have developed a new method that uses artificial intelligence to foresee the most likely mutations of pathogens like SARS-COV-2, the virus that causes COVID-19. The new research has implications for the rapid development of vaccines, treatments and diagnostic tests that would be much less likely to be impacted by new or emerging variants of concern.
Cancer chemotherapy drug reverses Alzheimer’s symptoms in mice
A drug commonly used to treat cancer can restore memory and cognitive function in mice that display symptoms of Alzheimer's disease, new UBC research has found. The drug, Axitinib, inhibits the growth of new blood vessels in the brain-a feature shared by both cancer tumours and Alzheimer's disease, but this hallmark represents a new target for Alzheimer's therapies.
A drug commonly used to treat cancer can restore memory and cognitive function in mice that display symptoms of Alzheimer's disease, new UBC research has found. The drug, Axitinib, inhibits the growth of new blood vessels in the brain-a feature shared by both cancer tumours and Alzheimer's disease, but this hallmark represents a new target for Alzheimer's therapies.
Discovery of mechanics of drug targets for COVID-19
A team of international researchers, including McGill Professor Stéphane Laporte , have discovered the working mechanism of potential drug targets for various diseases such as cancer, rheumatoid arthritis, and even COVID-19. The findings published in Molecular Cell uncover the inner workings of cell receptors that are involved in cancer progression and inflammatory diseases.
A team of international researchers, including McGill Professor Stéphane Laporte , have discovered the working mechanism of potential drug targets for various diseases such as cancer, rheumatoid arthritis, and even COVID-19. The findings published in Molecular Cell uncover the inner workings of cell receptors that are involved in cancer progression and inflammatory diseases.
Busting myths about COVID-19 vaccines and fertility
It can be difficult to separate fact from fiction when it comes to COVID-19 vaccines, particularly in relation to fertility and reproductive health. UBC's Dr. Deborah Money, professor in the faculty of medicine's department of obstetrics and gynaecology, busts some of the many myths circulating about the vaccines' impact on fertility.
It can be difficult to separate fact from fiction when it comes to COVID-19 vaccines, particularly in relation to fertility and reproductive health. UBC's Dr. Deborah Money, professor in the faculty of medicine's department of obstetrics and gynaecology, busts some of the many myths circulating about the vaccines' impact on fertility.
Access to essential cancer medicines is unequal globally
KINGSTON, ON, September 21, 2021 - Patients in most countries of the world do not have access to basic cancer medicines, according to new research from Queen's University professor Christopher Booth and collaborators at the World Health Organization (WHO). Their paper , published in The Lancet Oncology , asked oncologists worldwide to list the most important cancer medicines and to describe whether patients could access these medicines in their home country.
KINGSTON, ON, September 21, 2021 - Patients in most countries of the world do not have access to basic cancer medicines, according to new research from Queen's University professor Christopher Booth and collaborators at the World Health Organization (WHO). Their paper , published in The Lancet Oncology , asked oncologists worldwide to list the most important cancer medicines and to describe whether patients could access these medicines in their home country.
Chemotherapy drug puts young children with cancer at high risk of hearing loss
75 per cent of patients five years old and younger had experienced cisplatin-related hearing loss three years after starting therapy A chemotherapy drug known to cause hearing loss in children is more likely to do so the earlier in life children receive it, new UBC research has found. Cisplatin is a life-saving treatment for many children with cancer, but the study published today in Cancer shows that the hearing of very young children is impacted early during treatment and is affected to a greater extent than that of older children.
75 per cent of patients five years old and younger had experienced cisplatin-related hearing loss three years after starting therapy A chemotherapy drug known to cause hearing loss in children is more likely to do so the earlier in life children receive it, new UBC research has found. Cisplatin is a life-saving treatment for many children with cancer, but the study published today in Cancer shows that the hearing of very young children is impacted early during treatment and is affected to a greater extent than that of older children.
Queen’s researcher develops new blood test for earlier cancer detection and optimization of treatment
A team of researchers at Queen's University, led by Dr. Christopher Mueller (Queen's Cancer Research Institute), have developed a new, cost effective cancer detection and characterization method based on the presence of circulating tumour DNA in the blood called mDETECT (methylation DETEction of Circulating Tumour DNA).
A team of researchers at Queen's University, led by Dr. Christopher Mueller (Queen's Cancer Research Institute), have developed a new, cost effective cancer detection and characterization method based on the presence of circulating tumour DNA in the blood called mDETECT (methylation DETEction of Circulating Tumour DNA).
Current cancer research efforts do not match the global burden of the disease
January 28 - A new study involving scientists at Queen's University has found that current cancer research efforts do not match the global burden of deaths from the disease. The research was led by Christopher Booth, Professor of Oncology and Public Health Sciences and Canada Research Chair in Population Cancer Care.
January 28 - A new study involving scientists at Queen's University has found that current cancer research efforts do not match the global burden of deaths from the disease. The research was led by Christopher Booth, Professor of Oncology and Public Health Sciences and Canada Research Chair in Population Cancer Care.
Event - Mar 22
'All are welcome': University of Toronto Mississauga to host inaugural All-Nations Powwow
'All are welcome': University of Toronto Mississauga to host inaugural All-Nations Powwow

Social Sciences - Mar 21
'We all need to be changemakers': University of Toronto marks International Day for the Elimination of Racial Discrimination
'We all need to be changemakers': University of Toronto marks International Day for the Elimination of Racial Discrimination

Career - Mar 21
'An amazing experience': University of Toronto Engineering students explore careers through PEY Co-op program
'An amazing experience': University of Toronto Engineering students explore careers through PEY Co-op program

Innovation - Mar 21
Mila and UNESCO join forces to emphasize the urgent need for better AI governance
Mila and UNESCO join forces to emphasize the urgent need for better AI governance

Pharmacology - Mar 21
Can pharmacies offer frontline support to victims of intimate partner violence?
Can pharmacies offer frontline support to victims of intimate partner violence?
Social Sciences - Mar 20
A bitter truth: 30 years of child welfare data reveals systemic inequities, racism and harm
A bitter truth: 30 years of child welfare data reveals systemic inequities, racism and harm
Campus WATERLOO - Mar 17
Waterloo makes campus more inclusive for Two-Spirit, Trans and Non-Binary community members
Waterloo makes campus more inclusive for Two-Spirit, Trans and Non-Binary community members